drugset
drugset / Trial / NCT04590625

Apatinib Combined With Abraxane and Carboplatin or Cisplatinum as First-line Treatment for Epithelial Ovarian Cancer

NCT04590625 ↗

Phase 2 Unknown 58 enrolled Zhongshan Hospital Xiamen University
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This monocentric, prospective, observational study will evaluate the safety and efficacy of apatinib in combination with albumin binds paclitaxel and carboplatin or cisplatinum as first-line treatment for stage II-IV epithelial ovarian cancer followed by apatinib maintenance therapy in routine clinical practice. Eligible patients will be followed for approximately 20 months.

Timeline

Start
2020-10
Primary completion
2022-10
Completion
2023-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Rivoceranib Small molecule 250 mg Oral
Background Abraxane Small molecule 260 mg/m2 Intravenous
Background Carboplatin Small molecule 5 unknown Intravenous
Background Carboplatin Small molecule 6 unknown Intravenous
Background Cisplatin Other / unclassified 75 mg/m2 Other
Background Cisplatin Other / unclassified 100 mg/m2 Other

Indications

ovarian carcinoma